Patents Assigned to PF Argentum IP Holdings LLC
  • ENHANCEMENT OF CD47 BLOCKADE THERAPY WITH DHFR INHIBITORS
    Publication number: 20240423983
    Abstract: Materials and methods useful for therapy, including cancer therapy, that combine an agent that blocks the CD47/SIRP? interaction with a DHFR inhibitor are provided.
    Type: Application
    Filed: April 25, 2022
    Publication date: December 26, 2024
    Applicant: PF Argentum IP Holdings LLC
    Inventors: Robert Adam UGER, Gloria Hoi Ying LIN
  • Enhancement of CD47 blockade therapy by proteasome inhibitors
    Patent number: 11446315
    Abstract: CD47? disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRP?Fc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 20, 2022
    Assignee: PF Argentum IP Holdings LLC
    Inventors: Emma Linderoth, Natasja Nielsen Viller, Robert Adam Uger, Penka Slavcheva Slavova-Petrova